Skip to content

Study · Randomized controlled trial · n = 281 · 2022

5 results

Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.

Lambertini M, Boni L, Michelotti A, Magnolfi E, Cogoni AA, Mosconi AM, Giordano M, Garrone O, Arpino G, Poggio F, Cinacchi P, Bighin C and 4 more

Show all authors

Fregatti P, Pronzato P, Blondeaux E, Del Mastro L

Journal of the National Cancer Institute1 Mar 2022Cited by 33 (Europe PMC)

PMID34850043 (opens in a new tab)PMCIDPMC8902441 (opens in a new tab)DOI10.1093/jnci/djab213 (opens in a new tab)PepBankPUB-34850043
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In premenopausal patients with early breast cancer, adding triptorelin to chemotherapy did not change 12-year disease-free survival versus chemotherapy alone.

    In plain wordsIn patients with early breast cancer, triptorelin plus chemotherapy gave similar disease-free survival to chemotherapy alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant change12-year disease-free survival
    Study

    n = 281

    Comparator
    Chemotherapy alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Disease-free survival
    65.7%
    triptorelin arm
    Disease-free survival
    69.2%
    control arm
    HR
    1.16 unitless
    versus chemotherapy alone

    Source sentences

    Summary
    No differences in 12-year DFS (65.7% [95% CI = 57.0% to 73.1%] in the GnRHa arm vs 69.2% [95% CI = 60.3% to 76.5%] in the control arm; HR = 1.16, 95% CI = 0.76 to 1.77)
    2 context sentences
    Summary · context
    Eligible patients were randomly assigned to (neo)adjuvant chemotherapy alone (control arm) or combined with the GnRHa triptorelin (GnRHa arm).
    Summary · context
    Post hoc endpoints were disease-free survival (DFS), overall survival (OS), and post-treatment pregnancies.
  2. 02HumanRandomized controlled trialSafety outcome

    In premenopausal patients with early breast cancer, adding triptorelin to chemotherapy did not change 12-year overall survival versus chemotherapy alone.

    In plain wordsIn patients with early breast cancer, triptorelin plus chemotherapy gave similar overall survival to chemotherapy alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant change12-year overall survival
    Study

    n = 281

    Comparator
    Chemotherapy alone
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Measurements

    Overall survival
    81.2%
    triptorelin arm
    Overall survival
    81.3%
    control arm
    HR
    1.17 unitless
    versus chemotherapy alone

    Source sentences

    Summary
    or in 12-year OS (81.2% [95% CI = 73.6% to 86.8%] in the GnRHa arm vs 81.3% [95% CI = 73.1% to 87.2%] in the control arm; HR = 1.17, 95% CI = 0.67 to 2.03) were observed.
    2 context sentences
    Summary · context
    Eligible patients were randomly assigned to (neo)adjuvant chemotherapy alone (control arm) or combined with the GnRHa triptorelin (GnRHa arm).
    Summary · context
    Post hoc endpoints were disease-free survival (DFS), overall survival (OS), and post-treatment pregnancies.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In premenopausal patients with early breast cancer, post-treatment pregnancies numbered 9 with triptorelin plus chemotherapy versus 4 with chemotherapy alone.

    In plain wordsIn patients with breast cancer, 9 pregnancies followed triptorelin plus chemotherapy versus 4 after chemotherapy alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePost-treatment pregnancy
    Study

    n = 281

    Comparator
    Chemotherapy alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Post-treatment pregnancies
    9 patients
    triptorelin arm
    Post-treatment pregnancies
    4 patients
    control arm
    Pregnancy HR
    2.14 unitless
    versus chemotherapy alone

    Source sentences

    Summary
    In the GnRHa and control arms, 9 and 4 patients had a posttreatment pregnancy, respectively (HR = 2.14, 95% CI = 0.66 to 6.92).
    2 context sentences
    Summary · context
    Eligible patients were randomly assigned to (neo)adjuvant chemotherapy alone (control arm) or combined with the GnRHa triptorelin (GnRHa arm).
    Summary · context
    Post hoc endpoints were disease-free survival (DFS), overall survival (OS), and post-treatment pregnancies.
  4. 04HumanRandomized controlled trialSafety outcome

    In hormone receptor-positive early breast cancer, triptorelin plus chemotherapy gave a disease-free survival HR of 1.02 versus chemotherapy alone.

    In plain wordsIn hormone receptor-positive breast cancer, disease-free survival was similar with triptorelin plus chemotherapy and chemotherapy alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeDisease-free survival in hormone receptor-positive disease
    Study

    n: not reported in source

    Comparator
    Chemotherapy alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    DFS HR
    1.02 unitless
    hormone receptor-positive disease

    Source sentences

    Summary
    In patients with hormone receptor-positive disease, the hazard ratio was 1.02 (95% CI = 0.63 to 1.63) for DFS and 1.12 (95% CI = 0.59 to 2.11) for OS.
    2 context sentences
    Summary · context
    Eligible patients were randomly assigned to (neo)adjuvant chemotherapy alone (control arm) or combined with the GnRHa triptorelin (GnRHa arm).
    Summary · context
    Post hoc endpoints were disease-free survival (DFS), overall survival (OS), and post-treatment pregnancies.
  5. 05HumanRandomized controlled trialSafety outcome

    In hormone receptor-positive early breast cancer, triptorelin plus chemotherapy gave an overall survival HR of 1.12 versus chemotherapy alone.

    In plain wordsIn hormone receptor-positive breast cancer, overall survival was similar with triptorelin plus chemotherapy and chemotherapy alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeOverall survival in hormone receptor-positive disease
    Study

    n: not reported in source

    Comparator
    Chemotherapy alone
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Measurements

    OS HR
    1.12 unitless
    hormone receptor-positive disease

    Source sentences

    Summary
    In patients with hormone receptor-positive disease, the hazard ratio was 1.02 (95% CI = 0.63 to 1.63) for DFS and 1.12 (95% CI = 0.59 to 2.11) for OS.
    2 context sentences
    Summary · context
    Eligible patients were randomly assigned to (neo)adjuvant chemotherapy alone (control arm) or combined with the GnRHa triptorelin (GnRHa arm).
    Summary · context
    Post hoc endpoints were disease-free survival (DFS), overall survival (OS), and post-treatment pregnancies.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.